Fluidigm Corporation is a Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies.
Fluidigm Corporation (FLDM) had a rough trading day for Monday February 22 as shares tumbled 10.21%, or a loss of $-0.625 per share, to close at $5.50. After opening the day at $6.13, shares of Fluidigm Corporation traded as high as $6.13 and as low as $5.45. Volume was 3.7 million shares over 16,470 trades, against an average daily volume of n/a shares and a total float of 74.12 million.
As a result of the decline, Fluidigm Corporation now has a market cap of $407.28 million. In the last year, shares of Fluidigm Corporation have traded between a range of $12.45 and $1.17, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. It sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm’s revenue comes from the sale of Consumables. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of revenue is generated in the United States followed by EMEA and Asia-Pacific.
Fluidigm Corporation is based out of South San Francisco, CA and has some 566 employees. Its CEO is Stephen Christopher Linthwaite.